REVIEW PAPER
Physiological and pathophysiological implications of osteopontin and the diagnostic utility of the protein in kidney diseases
 
 
More details
Hide details
1
Department of Pharmacology, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, ul. G. Herlinga-Grudzińskiego 1C, 30-705 Krakow, Poland
CORRESPONDING AUTHOR
Lukasz Dobrek   

Department of Pharmacology, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, ul. G. Herlinga-Grudzińskiego 1C, 30-705 Krakow, Poland, Gustawa Herlinga-Grudzińskiego 1, 30-705 Krakow, Poland
 
J Pre Clin Clin Res. 2018;12(1):6–10
KEYWORDS
TOPICS
ABSTRACT
Introduction and objective:
Osteopontin (OPN) is a protein playing many pleiotropic both physiological and pathophysiological roles in various organs. The paper briefly characterizes both the positive and negative roles of OPN, with particular emphasis on the role of the protein in kidney functioning.

Brief description of the state of knowledge:
As its name suggests, OPN is a protein mainly regulating bone homeostasis, but it also participates in the pathogenesis of inflammation, neoplasm, atherosclerosis and vascular calcification. OPN is also an important protein involved in kidney physiology. Its main physiological function is to act as an inhibitor of the crystallization of urine mineral components and to prevent kidney stones formation. OPN is also overproduced in various kidney pathologies (tubulointerstitial fibrosis, crescending glomerulonephritis, cyclosporine or diabetic nephropathy, renal ischemia reperfusion injury), and both experimental and clinical studies suggest that OPN may exert either a protective or detrimental effect on kidneys.

Conclusions:
Considering the OPN role in kidneys, the protein is currently proposed as one of novel laboratory biomarkers for renal function. OPN, along with the other proteins found in the urine in various kidney diseases (neutrophil gelatinaseassociated lipocalin-1, kidney injury molecule-1, and fatty acid binding protein) is a part of the laboratory panel that will be gradually introduced into common laboratory practice.

 
REFERENCES (58)
1.
Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med. 2000; 11(3): 279‒303.
 
2.
Franzen A, Heinegard D. Isolation and characterization of two sialoproteins present only on bone calcified matrix. Biochem J. 1985; 232: 715-724.
 
3.
Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci USA 1986; 83: 8819-8823.
 
4.
Fisher LW, Hawkins GR, Tuross N, Termine JD. Purification and partial characterization of small proteoglycans I and II, bone sialoproteins I and II and osteonectin from the mineral compartment of developing human bone. J Biol Chem. 1987; 262: 9702-9708.
 
5.
Prince CW, Oosawa T, Butler WT, Tomana M, Bhown AS, Bhown M, et al. Isolation, characterization and biosynthesis of a phosphorylated glycoprotein from rat bone. J Biol Chem., 1987; 262: 2900-2907.
 
6.
Tamma R, Carbone C, Colucci S. Bone matrix proteins and mineralization process. In: Albanese CV, Faletti C, editors. Imaging of prosthetic joints. Springer, Milano, 2014. p. 15-25.
 
7.
Sroga GE, Vashishth D. Effects of bone matrix proteins on fracture and fragility in osteoporosis. Curr Osteoporos Rep. 2012; 10(2): 141-150.
 
8.
Boskey AL. Bone composition: relationship to bone fragility and antiosteoporotic drug effects. BoneKEy Reports 2013; 2: article number 447.
 
9.
Hunter GK. Role of osteopontin in modulation of hydroxyapatite formation. Calcif Tissue Int. 2013; 93(4): 348‒354.
 
10.
de Bruyn JR, Goiko M, Mozaffari M, Bator D, Dauphinee RL, Liao Y, et al. Dynamic light scattering study of inhibition of nucleation and growth of hydroxyapatite crystals by osteopontin. PLoS ONE 2013; 8(2): e56764.
 
11.
Pampena DA, Robertson KA, Litvinova O, Lajoie G, Goldberg HA, Hunter GK. Inhibition of hydroxyapatite formation by osteopontin phosphopeptides. Biochem J. 2004; 378: 1083 1087.
 
12.
Rittling SR, Denhardt DT. Osteopontin function in pathology: lessons from osteopontin deficient mice. Exp Nephrol. 1999; 7: 103-113.
 
13.
Duong LT, Lakkakorpi T, Nakamura I, Rodan GA. Integrins and signaling in osteoclast function. Matrix Biol. 2000; 19(2): 97-105.
 
14.
Nakamura I, Duong LT, Rodan SB, Rodan GA. Involvement of alpha(v)beta3 integrins in osteoclasts function. J Bone Miner Metab. 2007; 25(6): 337-344.
 
15.
O’Regan A, Berman JS. Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exper Pathol. 2000; 81: 373-390.
 
16.
Courter D, Cao H, Kwok S, Kong C, Banh A, Kuo P, et al. The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways. PLoS ONE 2010; 5(3): e9633.
 
17.
Goldberg HA, Warner KJ, Li MC, Hunter GK. Binding of bone sialoprotein, osteopontin and synthetic polypeptides to hydroxyapatite. Connect Tissue Res. 2001; 42(1): 25-37.
 
18.
Cho HJ, Cho HJ, Kim HS. Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis and vascular calcification. Curr Atherosc Rep. 2009; 11: 206-213.
 
19.
Pullig O, Weseloh G, Gauer S, Swoboda B. Osteopontin is expressed by adult human osteoarthritic chondrocytes: protein and mRNA analysis of normal and osteoarthritic cartilage. Matrix Biol. 2000; 19: 245-255.
 
20.
Xie Z, Singh M, Siwik DA, Joyner WL, Singh K. Osteopontin inhibits interleukin-1beta-stimulated increases in matrix metalloproteinase activity in adult rat cardiac fibroblasts: roleof protein kinase C-zeta. J Biol Chem. 2003; 278: 48546-48552.
 
21.
Lund SA, Giachelli CM, Scatena M. The role of osteopontin in inflammatory processes. JCell Commun Signal. 2009; 3: 311-322.
 
22.
Tokairin T, Nishikawa Y, Watanabe H, Doi Y, Omori Y, Yoshioka T, et al. Osteopontin expression in the liver with severe perisinusoidal fibrosis: autopsy case of down syndrome with transient myeloproliferative disorder. Pathol Int. 2008; 58: 64‒68.
 
23.
Sodhi CP, Phadke SA, Batlle D, Sahai A. Hypoxia stimulates osteopontin expression and proliferation of cultured vascular smooth muscle cells: potentiation by high glucose. Diabetes 2001; 50: 1482-1490.
 
24.
Zanotti S, Gibertini S, Di Blasi C, Cappelletti C, Bernasconi P, Mantegazza R, et al. Osteopontin is highly expressed in severely dystrophic muscle and seems to play a role in muscle regeneration and fibrosis. Histopathology 2011: 59: 1215-1228.
 
25.
Singh K, Balligand JL, Fischer TA, Smith TW, Kelly RA. Glucocorticoids increase osteopontin expression in cardiac myocytes and microvascular endothelial cells. Role in regulation of inducible nitric oxide synthase. J Biol Chem. 1995; 270: 28471-28478.
 
26.
Davis RL, Lopez CA, Mou K. Expression of osteopontin in the inner ear. Ann N Y Acad Sci. 1995; 760: 279-295.
 
27.
Shin SL, Cha JH, Chun MH, Chung JW, Lee MY. Expression of osteopontin mRNA in the adult rat brain. Neurosci Lett. 1999; 273: 73-76.
 
28.
Nemir M, Bhattacharyya D, Li X, Singh K, Mukherjee AB, Mukherjee BB. Targeted inhibition of osteopontin expression in the mammary gland causes abnormal morphogenesis and lactation deficiency. J Biol Chem. 2000; 275: 969-976.
 
29.
Zhang ZX, Shek K, Wang S, Huang X, Lau A, Yin Z et al. Osteopontin expressed in tubular epithelial cells regulates NK cell-mediated kidney ischemia reperfusion injury. J Immunol. 2010; 185: 967-973.
 
30.
Kahles F, Findeisen HM, Bruemmer D. Osteopontin: a novel regulator at the cross roads of the inflammation, obesity and diabetes. Mol Metab. 2014; 3: 384-393.
 
31.
Guo H, Cai CQ, Schroeder RA, Kuo PC. Osteopontin is a negative feedback regulator of nitric oxide synthesis in murine macrophages. J Immunol. 2001; 166: 1079-1096.
 
32.
Wai PY, Guo L, Gao C, Mi Z, Guo H, Kuo PC. Osteopontin inhibits macrophage nitric oxide synthesis to enhance tumor proliferation. Surgery 2006; 140(2): 132-140.
 
33.
Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol. 2007; 27: 2302-2309.
 
34.
Mori R, Shaw TJ, Martin P. Molecular mechanisms linking wound inflammation and fibrosis: knockdown of Osteopontin leads to rapid repair and reduced scarring. J Exp Med. 2008; 205: 43-51.
 
35.
Miyazaki K, Okada Y, Yamanaka O, Kitano A, Ikeda K, Kon S, et al. Corneal wound healing in an Osteopontin-deficient mouse. Invest Ophtalmol Vis Sci. 2008; 49(4): 1367-1375.
 
36.
Iyer SS, Cheng G. Role of interleukin-10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol. 2012; 32(1): 23-63.
 
37.
Hamza T, Barnett JB, Li B. Interleukin 12 a key immunoregulatory cytokine in infection applications. Int J Mol Sci. 2010; 11: 789-806.
 
38.
Shevde LA, Samant RS. Role of osteopontin in the pathophysiology of cancer. Matrix Biol. 2014; 37: 131-141.
 
39.
Georgiadou P, Iliodromitis EK, Varounis C, Mavroidis M, Kolokathis F, Andreadou I, et al. Relationship between plasma osteopontin and oxidative stress in patients with coronary artery disease. Expert Opin Ther Targets 2008; 12: 917-920.
 
40.
Yim HE, Yoo KH. Osteopontin and developing kidney. J Korean Soc Pediatr Nephrol. 2006; 10: 1-7.
 
41.
Rogers SA, Padanilam BJ, Hruska KA, Giachelli CM, Hammerman MR. Metanephric osteopontin regulates nephrogenesis in vitro. Am J Physiol. 1997; 272: F469-F476.
 
42.
Wesson JA, Johnson RJ, Mazzali M, Beshensky AM, Stietz S, Giachelli C, et al. Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J Am Soc Nephrol. 2003; 14: 139-147.
 
43.
Basavaraj DR, Biyani CH, Browning AJ, Cartledge JJ. The role of urinary kidney stone inhibitors and promoters in the pathogenesis of calcium containing renal stones. EAU-EBU Update Series 2007; 5: 126-136.
 
44.
Mohamaden WI, Wang H, Guan H, Meng X, Li J. Osteopontin and Tamm Horsefall proteins – macromolecules of myriad values. J Basic Appl Zool. 2014; 67: 158-163.
 
45.
Nagao T, Okura T, Irita J, Jotoku M, Enomoto D, Desilva VR, et al. Osteopontin plays a critical role in interstitial fibrosis but not glomerular sclerosis in diabetic nephropathy. Nephron Extra 2012; 2: 87-103.
 
46.
Yano R, Golbar HM, Izawa T, Sawamoto O, Kuwamura M, Yamate J. Participation of bone morphogenetic protein (BMP)-6 and osteopontin in cisplatin (CDDP)-induced rat renal fibrosis. Exp Toxicol Pathol. 2015; 67(2): 99-107.
 
47.
Hudkins KL, Giachelli CM, Eitner F, Couser WG, Johnson RJ, Alpers CE. Osteopontin expression in human crescentic glomerulonephritis. Kidney Int. 2000; 57: 105-116.
 
48.
Wasilewska A, Taranta-Janusz K, Kuroczycka-Saniutycz E, Zoch-Zwierz W. Urinary OPN excretion in children with glomerular proteinuria. Adv Med Sci. 2011; 56(2): 193-199.
 
49.
Mazzali M, Hughes J, Dantas M, Liaw L, Steitz S, Alpers CE, et al. Effects of cyclosporine in osteopontin null mice. Kidney Int. 2002; 62: 78-85.
 
50.
Lim BJ, Kim PK, Hong SW, Jeong HJ. Osteopontin expression and microvascular injury in cyclosporine nephrotoxicity. Pediatr Nephrol. 2004; 19(3): 288-294.
 
51.
Nicholas SB, Liu J, Kim J, Ren Y, Collins AR, Nguyen L, et al. Critical role for osteopontin in diabetic nephropathy. Kidney Int. 2010; 77: 588-600.
 
52.
Al-Malki AL. Assessment of urinary osteopontin in association with podocyte for early predication of nephropathy in diabetic patients. Dis Markers. 2014; 2014:493736.
 
53.
Cen C, Aziz M, Yang WL, Nicastro JM, Coppa GF, Wang P. Osteopontin blockade attenuates renal injury after ischemia reperfusion by inhibiting NK cell infiltration. Shock 2017; 47(1): 52-60.
 
54.
Wolak T, Kim HJ, Ren Y, Kim J, Vaziri ND, Nicholas SB. Osteopontin modulates angiotensin II–induced inflammation, oxidative stress, and fibrosis of the kidney. Kidney Int. 2009; 76: 32-43.
 
55.
Okada H, Moriwaki K, Kalluri R, Takenaka T, Imai H, Ban S, et al. Osteopontin expressed by renal tubular epithelium mediates interstitial monocyte infiltration in rats. Am J Physiol Renal Physiol. 2000; 278: F110-F121.
 
56.
Yu XQ, Wu LL, Huang XR, Yang N, Gilbert RE, Cooper ME, et al. Osteopontin expression in progressive renal injury in remnant kidney: role of angiotensin II. Kidney Int. 2000; 58: 1469-1480.
 
57.
Irita J, Okura T, Jotoku M, Nagao T, Enomoto D, Kurata M, et al. Osteopontin deficiency protects against aldosterone-induced inflammation, oxidative stress, and interstitial fibrosis in the kidney. Am J Physiol Renal Physiol. 2011; 301: F833-F844.
 
58.
Ferguson MA, Waikar SS. Established and emerging markers of kidney function. Clin Chem. 2012; 58(4): 680-689.
 
eISSN:1898-7516
ISSN:1898-2395